Fisher Asset Management LLC Sells 556,620 Shares of Sanofi $SNY

Fisher Asset Management LLC trimmed its holdings in shares of Sanofi (NASDAQ:SNY) by 4.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,578,746 shares of the company’s stock after selling 556,620 shares during the period. Fisher Asset Management LLC’s holdings in Sanofi were worth $593,717,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in SNY. Aviso Financial Inc. raised its holdings in shares of Sanofi by 4.7% in the 3rd quarter. Aviso Financial Inc. now owns 47,144 shares of the company’s stock valued at $2,225,000 after purchasing an additional 2,109 shares in the last quarter. American Century Companies Inc. increased its holdings in Sanofi by 19.4% during the third quarter. American Century Companies Inc. now owns 2,338,969 shares of the company’s stock valued at $110,399,000 after buying an additional 379,784 shares during the period. Harvest Portfolios Group Inc. raised its stake in Sanofi by 7.5% in the third quarter. Harvest Portfolios Group Inc. now owns 37,400 shares of the company’s stock worth $1,765,000 after buying an additional 2,600 shares in the last quarter. AlphaCore Capital LLC lifted its holdings in Sanofi by 441.9% during the third quarter. AlphaCore Capital LLC now owns 15,234 shares of the company’s stock worth $719,000 after buying an additional 12,423 shares during the period. Finally, TD Asset Management Inc lifted its holdings in Sanofi by 20.9% during the third quarter. TD Asset Management Inc now owns 337,539 shares of the company’s stock worth $15,932,000 after buying an additional 58,252 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Barclays downgraded Sanofi from an “overweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. Wall Street Zen downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. UBS Group reissued a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Finally, Citigroup began coverage on shares of Sanofi in a report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Five equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $62.67.

Sanofi Trading Up 0.6%

Shares of NASDAQ:SNY opened at $48.66 on Monday. The business’s 50-day moving average is $47.54 and its 200 day moving average is $48.58. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The firm has a market capitalization of $118.68 billion, a P/E ratio of 13.52, a P/E/G ratio of 1.26 and a beta of 0.45.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.